Spyre Therapeutics Inc (SYRE) FinancialsSYREFinancialSpyre Therapeutics Inc

Evaluating the bottom line, Spyre Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -28.52%, provide a clear picture of how effectively SYRE converts its operational activities into shareholder value.

In the context of the broader market, SYRE competes directly with industry leaders such as ALKS and TGTX. With a market capitalization of $8.25B, it holds a leading position in the sector. When comparing efficiency, SYRE's gross margin of N/A stands against ALKS's 75.67% and TGTX's 82.86%. Such benchmarking helps identify whether Spyre Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Spyre has reported substantial net losses, with a net income of -$69 million for Q1 2026 and a forward P/E ratio of 0, indicating no earnings expected in the near future. The company has a current ratio of 18.53, suggesting strong liquidity, but the negative earnings trend is concerning.